secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001641489-24-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track
--------------------------------------------------------------------------------

- Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.
- Net loss $4.9M ($1.17/share) vs $4.5M ($2.16/share) in Q1 2023; revenue $1.0M from milestone.
- R&D spend $2.6M, down from $3.9M YoY; G&A $4.0M, up from $3.5M.
- First Phase 3 cadisegliatin trial in T1D expects first patient enrollment Q2 2024, top-line data Q1 2026.
- Planning two international registrational trials for cadisegliatin in T1D starting 2026; T2D Phase 2 in Middle East on track H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/0001641489-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/vtvt-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001641489-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer